8-KLeadership ChangesExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Executive Changes (Oct 15, 2013)

Filed October 15, 2013For Securities:JNJ

Summary

Johnson & Johnson (JNJ) announced a significant addition to its Board of Directors, appointing Dr. Mark B. McClellan, a prominent figure in health economics and policy from the Brookings Institution, effective October 15, 2013. This appointment brings a wealth of expertise in healthcare value and innovation, which is particularly relevant given the evolving healthcare landscape and JNJ's diversified business across pharmaceuticals, medical devices, and consumer health. Dr. McClellan's role on the Regulatory, Compliance & Government Affairs Committee and the Science, Technology & Sustainability Committee suggests a strategic focus on navigating regulatory challenges, ensuring compliance, and driving innovation. Investors should view this as a positive development, indicating the company's commitment to strengthening its board with independent expertise to guide its long-term strategy and enhance stakeholder value, especially in areas critical to the company's future growth and market positioning.

Key Highlights

  • 1Appointment of Dr. Mark B. McClellan to the Board of Directors, effective October 15, 2013.
  • 2Dr. McClellan brings expertise from the Brookings Institution, focusing on health economics and innovation.
  • 3He will serve on the Regulatory, Compliance & Government Affairs Committee and the Science, Technology & Sustainability Committee.
  • 4This appointment adds independent expertise to the board, crucial for navigating the complex healthcare industry.
  • 5The company views this as a move to strengthen strategic guidance and stakeholder value.
  • 6Dr. McClellan will receive standard compensation for non-employee directors as outlined in the company's proxy statement.

Frequently Asked Questions

Dr. Mark B. McClellan is a Senior Fellow in Economic Studies and Director of the Initiative on Value and Innovation in Health Care at the Brookings Institution. His appointment is significant because it brings specialized knowledge in health economics, policy, and innovation to Johnson & Johnson's Board of Directors, which can help guide the company's strategy in a rapidly changing healthcare environment.

Dr. McClellan will serve on two key committees: the Regulatory, Compliance & Government Affairs Committee and the Science, Technology & Sustainability Committee.

As a non-employee director, Dr. McClellan will receive compensation in accordance with the practices described in Johnson & Johnson's 2013 Proxy Statement for its directors.

This is an addition to the Board of Directors, not a change in executive management or day-to-day operations. While it brings new strategic oversight, it does not represent a fundamental shift in the company's operational structure or executive leadership team.